Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Accumulated Expenses (2017 - 2025)

Historic Accumulated Expenses for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $37.1 million.

  • Puma Biotechnology's Accumulated Expenses fell 2673.8% to $37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.1 million, marking a year-over-year decrease of 2673.8%. This contributed to the annual value of $36.9 million for FY2024, which is 3001.27% down from last year.
  • Puma Biotechnology's Accumulated Expenses amounted to $37.1 million in Q3 2025, which was down 2673.8% from $31.8 million recorded in Q2 2025.
  • Puma Biotechnology's Accumulated Expenses' 5-year high stood at $92.6 million during Q4 2021, with a 5-year trough of $26.9 million in Q1 2025.
  • Its 5-year average for Accumulated Expenses is $49.6 million, with a median of $39.7 million in 2022.
  • In the last 5 years, Puma Biotechnology's Accumulated Expenses surged by 5095.8% in 2021 and then tumbled by 5627.88% in 2022.
  • Over the past 5 years, Puma Biotechnology's Accumulated Expenses (Quarter) stood at $92.6 million in 2021, then plummeted by 42.71% to $53.0 million in 2022, then fell by 0.59% to $52.7 million in 2023, then crashed by 30.01% to $36.9 million in 2024, then grew by 0.59% to $37.1 million in 2025.
  • Its Accumulated Expenses stands at $37.1 million for Q3 2025, versus $31.8 million for Q2 2025 and $26.9 million for Q1 2025.